论文部分内容阅读
目的观察达立通颗粒治疗糖尿病胃轻瘫患者的临床疗效与安全性。方法 64例糖尿病胃轻瘫患者随机分为试验组和对照组,各32例。对照组患者口服多潘立酮片,每次10 mg,每天3次;试验组在对照组的基础上给予达立通颗粒,每次6 g,每天3次,2组均连续治疗1个月。比较2组患者的临床疗效,患者的血浆胃动素水平、胃泌素水平及复发率,同时观察2组不良反应发生情况。结果试验组有效率为96.9%,显著高于对照组的78.1%(P<0.05)。治疗后,2组血浆胃动素、胃泌素水平均显著高于治疗前,试验组显著高于对照组(P<0.05)。治疗后半年以及1年后试验组的复发率均显著低于对照组(P<0.05)。对照组不良反应发生率为12.5%,显著高于试验组的3.1%,差异有统计学意义(P<0.05)。结论达立通颗粒对糖尿病胃轻瘫患者的临床疗效较好,显著改善患者的血浆胃肠激素水平。
Objective To observe the clinical efficacy and safety of Daridong Granules in the treatment of diabetic gastroparesis. Methods Sixty-four patients with diabetic gastroparesis were randomly divided into experimental group and control group, with 32 cases in each group. The patients in the control group were given oral domperidone tablets 10 mg once daily for 3 times. The experimental group was given Dalitong granules 6 g once daily for 3 days each on the basis of the control group, and the two groups were treated continuously for 1 month. The clinical curative effect, the level of plasma motilin, the level of gastrin and the relapse rate of the two groups were compared, and the incidence of adverse reactions in the two groups were also observed. Results The effective rate of the experimental group was 96.9%, which was significantly higher than that of the control group (78.1%, P <0.05). After treatment, the levels of plasma motilin and gastrin in the two groups were significantly higher than those before treatment, the experimental group was significantly higher than the control group (P <0.05). The relapse rate of the test group was significantly lower than that of the control group (P <0.05) after six months and one year after treatment. The incidence of adverse reactions in the control group was 12.5%, which was significantly higher than that in the experimental group (3.1%), the difference was statistically significant (P <0.05). Conclusion Daridong Granules in patients with diabetic gastroparesis clinical efficacy is good, significantly improve the level of plasma gastrointestinal hormone.